ethosuximide has been researched along with Angelman Syndrome in 3 studies
Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.
Angelman Syndrome: A syndrome characterized by multiple abnormalities, MENTAL RETARDATION, and movement disorders. Present usually are skull and other abnormalities, frequent infantile spasms (SPASMS, INFANTILE); easily provoked and prolonged paroxysms of laughter (hence happy); jerky puppetlike movements (hence puppet); continuous tongue protrusion; motor retardation; ATAXIA; MUSCLE HYPOTONIA; and a peculiar facies. It is associated with maternal deletions of chromosome 15q11-13 and other genetic abnormalities. (From Am J Med Genet 1998 Dec 4;80(4):385-90; Hum Mol Genet 1999 Jan;8(1):129-35)
| Excerpt | Relevance | Reference |
|---|---|---|
| "After several years without seizures, 24 out of 30 had a relapse, which was quickly stopped in 23 out of 30 patients." | 1.72 | [Epilepsy in Angelman syndrome]. ( Bobylova, MY; Glukhova, LY; Kuzmich, GV; Mukhin, KY; Pylayeva, OA, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bobylova, MY | 1 |
| Mukhin, KY | 1 |
| Kuzmich, GV | 1 |
| Glukhova, LY | 1 |
| Pylayeva, OA | 1 |
| Handforth, A | 1 |
| Delorey, TM | 1 |
| Homanics, GE | 1 |
| Olsen, RW | 1 |
| Sugiura, C | 1 |
| Ogura, K | 1 |
| Ueno, M | 1 |
| Toyoshima, M | 1 |
| Oka, A | 1 |
3 other studies available for ethosuximide and Angelman Syndrome
| Article | Year |
|---|---|
[Epilepsy in Angelman syndrome].
Topics: Angelman Syndrome; Anticonvulsants; Child; Electroencephalography; Epilepsy; Ethosuximide; Female; H | 2022 |
Pharmacologic evidence for abnormal thalamocortical functioning in GABA receptor beta3 subunit-deficient mice, a model of Angelman syndrome.
Topics: Angelman Syndrome; Animals; Anticonvulsants; Baclofen; Cerebral Cortex; Disease Models, Animal; Elec | 2005 |
High-dose ethosuximide for epilepsy in Angelman syndrome: implication of GABA(A) receptor subunit.
Topics: Angelman Syndrome; Anticonvulsants; Electroencephalography; Epilepsy; Ethosuximide; Female; Humans; | 2001 |